Survival outcomes Associated with Various Resistance Mechanisms of Osimertinib in Chinese Advanced Non-Small Cell Lung Cancer Patients

with

[1]  P. Jänne,et al.  Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies , 2018, Cancer.

[2]  C. Paweletz,et al.  Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib , 2018, JAMA oncology.

[3]  S. Digumarthy,et al.  Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. , 2018, Cancer discovery.

[4]  T. Salame,et al.  A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways , 2018, Clinical Cancer Research.

[5]  Yunpeng Liu,et al.  Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients , 2018, Clinical Cancer Research.

[6]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[7]  Yih-Leong Chang,et al.  Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study. , 2017, The Lancet. Respiratory medicine.

[8]  C. Liam,et al.  Small Cell Transformation and T790M Mutation as Coresistance Mechanisms for First-line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy Failure. , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  B. Han,et al.  Capture‐Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA‐Releasing Capability in Advanced Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  M. Ahn,et al.  Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer , 2017, The New England journal of medicine.

[11]  S. Ou,et al.  High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression. , 2016, Lung cancer.

[12]  Erich P Huang,et al.  RECIST 1.1-Update and clarification: From the RECIST committee. , 2016, European journal of cancer.

[13]  H. Ji,et al.  Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors , 2016, Clinical Cancer Research.

[14]  J. Ahn,et al.  Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment. , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  Dong-Wan Kim,et al.  Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  J. Austin,et al.  The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  D. Planchard,et al.  EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Ash A. Alizadeh,et al.  FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution , 2014, Bioinform..

[19]  Pablo Cingolani,et al.  © 2012 Landes Bioscience. Do not distribute. , 2022 .

[20]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[21]  S. Digumarthy,et al.  Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.

[22]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[23]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[24]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[25]  John R. Engen,et al.  Novel mutant-selective EGFR kinase inhibitors against EGFR T790M , 2009, Nature.

[26]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .